Exhibit 10.48


 





 


October 11, 2017


 


Adam Logal


Opko


4400 Biscayne Blvd.


Miami, Florida 33129


 


 


Dear Adam:


This Letter Agreement (the “Agreement”)
is to confirm the terms of your proposed appointment on August 14, 2017 (the “Effective Date”) as a non-employee, independent
Director of Xenetic Biosciences, Inc. (the “Company”).


 


Overall, in terms of time commitment, we
expect your attendance at all the Board meetings and meetings of such committees of the Board that you will be appointed to (as
applicable). In addition, you will be expected to devote appropriate preparation time ahead of each meeting. By accepting this
appointment, you have confirmed that you are able to allocate sufficient time to meet the expectations of this position.


 


1.        Consideration.For and in consideration of the services to be performed by you, the Company agrees to compensate
you as follows:


 


	1.1	Director Fee. A director fee equal to $50,000 (Fifty Thousand U.S. Dollars) per annum, payable
quarterly (the “Board Meeting Fee”) will be the cash compensation for your role as a director, as well as any board
committees, as chair or as a member, you may participate.



 


	1.2	Stock Options. Subject to all approvals required by law, the Company will grant you, pursuant to an equity incentive
plan or such other plan to be adopted by the Company (the "Plan") and upon such terms and conditions as determined by
the Compensation Committee or the Board (as applicable), an option to purchase Twenty-Five Thousand (25,000) shares of common stock
of the Company at a strike price determined by the closing price of the common stock on the date of this Agreement (the “Initial
Grant”). This option shall be exercisable as provided herein and shall vest quarterly over twelve months so long as you are
a member of our board of directors. An additional option to purchase 25,000 shares of Company common stock shall be granted for
service each year at the date of the Company’s Annual Meeting of Shareholders commencing with the 2018 Annual Meeting of
Shareholders. The exercise price shall be determined by the closing price of the common stock on the date of such grant.



 


If your board service is terminated or
ends for any reason, all granted Options that have not vested – shall be forfeited, and any Options that have vested but
have not been exercised may be exercisable by you any time within three (3) months of the termination of your board position (the
“Termination Exercise Period”). Any Options that are not exercised within the Termination Exercise Period, shall expire
immediately.


 


1.2.1 Term of Options.
All Options, if and to the extent vested according to Section 1.2 above, shall be in effect for a period of 10 years commencing
immediately after the granting of all Options granted to you under this letter of appointment, and shall expire immediately thereafter,
unless terminated sooner as provided in Section 1.2. Without derogating from the aforesaid, if the Plan that shall be approved
by the Company shall include additional provisions related to expiration of Options, such provisions shall also apply with respect
to all Options granted to you under this letter of appointment.


 


 


 






    	 	1	 



     


    

 


1.2.1a Vesting. All Options granted
to you shall vest as provided in Section 1.2.


 


1.2.1b Price. The exercise price
of the Options shall be equal to the Company’s closing stock price on the date of your grant.


 


1.2.1c General. All options granted
to you shall be in effect subject to your continuous service as a Director and subject to the terms and conditions of the Company’s
Stock Option Plan (the “Plan”), including such terms related to vesting and expiration, and subject to such terms and
conditions as will be approved by the Company, at its sole discretion. In case of contradiction between the provisions of this
letter of appointment and the provisions of the Plan, the provisions of the Plan shall supersede.


 


1.2.1d Certain Representations.
You represent and agree that you are accepting the option to purchase shares of common stock being issued to you pursuant to this
Agreement for your own account and not with a view to or for sale of distribution thereof. You understand that the securities are
restricted securities and you understand the meaning of the term “restricted securities.” You further represent that
you were not solicited by publication of any advertisement in connection with the receipt of the shares and that you have consulted
tax counsel as needed regarding the shares.


 


1.3       Company agrees to
reimburse you for out-of-pocket expenses incurred by you in connection with your service (including out-of-pocket expenses, transportation,
and airfare on company business, provided that such expenses are against original and valid receipts (the “Expenses”).


 


1.4       Payment of the Expenses,
as applicable, shall be made against your itemized invoice following the receipt of the relevant invoice, which invoice shall
be submitted to the Company within seven (7) days of the end of each calendar month during the term of this letter of appointment.


 


1.5       For the
avoidance of any doubt, the Fee and the Options (subject to their terms) and the aforementioned Expenses constitute the full
and final consideration for your appointment, and you shall not be entitled to any additional consideration, of any form, for
your appointment and service.


 


2.        The term of your
appointment as a non-employee, director of the Company shall be for one year or until the next Meeting of Stockholders and
shall be renewable on a yearly basis by vote of the shareholders or appointment by the board.


 


3.          You
will undertake such travelling as may reasonably be necessary for the performance of your duties, including travelling for board
meetings and site visits if required.


 


4.          You will undertake such duties and powers relating to the Company and any subsidiaries or associated companies (the “Group”)
as the Board may from time to time reasonably request. The Board as a whole is collectively responsible for promoting the success
of the Company by directing and supervising the Company’s affairs, inter alia, as follows:


 


4.1       Providing entrepreneurial leadership of the Group within a framework of prudent and effective controls which enable risk to be assessed and managed; and




 


4.2       Setting the Group’s strategic aims, ensures that the necessary financial and human resources are in place for the Group to meet its objectives and reviews of management performance; and




 


4.3       Setting the Group’s values and standards and ensure that its obligations to its shareholders and others are understood and met.




 


 4.3.1 Managing conflicts of interest that may arise in board meetings; and




 


 4.3.2 Ensuring that all board members are acting in the best interests of all shareholders.




 


 


 






    	 	2	 



     


    

 


 5.       Confidential Information.




 


5.1      You undertake to the Company that you shall maintain in strict confidentiality all trade, business, technical or other information
regarding the Company, the Group, its affiliated entities and their business affairs including, without limitation, all marketing,
sales, technical and business know-how, intellectual property, trade secrets, identity and requirements of customers and prospective
customers, the Company’s methods of doing business and any and all other information relating to the operation of the Company
(collectively, the “Confidential Information”). You shall at no time disclose any Confidential Information to any person,
firm, or entity, for any purpose unless such disclosure is required in order to fulfil your responsibilities as director. You further
undertake that you shall not use such Confidential Information for personal gain.


 


“Confidential Information”
shall not include information that (i) is or becomes part of the public domain other than as a result of disclosure by You, (ii)
becomes available to you on a non-confidential basis from a source other than the Company, provided that the source is not bound
with respect to that information by a confidentiality agreement with the Group or is otherwise prohibited from transmitting that
information by a contractual legal or other obligation, or (iii) can be proven by you to have been in your possession prior to
disclosure of the information by the Company. In the event that you are requested or required (by oral questions, interrogatories,
requests for information or documents, subpoena, civil investigative demand or other process) to disclose any Confidential Information,
it is agreed that you, to the extent practicable under the circumstances, will provide the Company with prompt notice of any such
request or requirement so that the Company may seek an appropriate protective order or waive compliance with this paragraph 5.
If a protective order or the receipt of a waiver hereunder has not been obtained, you may disclose only that portion of the Confidential
Information which you are legally compelled to disclose.


 


5.2       Blackout
Period. You understand that we have, or intend to have, a policy pursuant to which no officer, director or key executive may not
engage in transactions in our stock during the period commencing the end of a fiscal quarter and ending the day after the financial
information for the quarter and year have been publicly released. If you become a member of the audit committee and you have information
concerning our financial results at any time, you may not engage in transactions in our securities until the information is publicly
disclosed.


 


6.       Term and Termination




 


6.1       Subject
to paragraph 6.2 hereunder, this appointment shall terminate immediately and without claim for compensation on the occurrence
of any of the following events:


 


 6.1.1 If you resign as a Director of the Company for any reason; and/or




 


 6.1.2 If you are removed or not re-appointed as a Director of the Board of the Company at a General Meeting of shareholders of the Company in accordance with the requirements of the Business Corporation Law of the State of Nevada and/or any other applicable law or regulation (the "Law") and/or the Company's Articles of Incorporation; and/or




 


 6.1.3 If you have been declared bankrupt or made an arrangement or composition with or for the benefit of your creditors; and/or




 


 6.1.4 If you have been disqualified from acting as a Director (including, but not limited to, an event in which you are declared insane or become of unsound mind or become physically incapable of performing your functions as director for a period of at least sixty (60) days; and/or




 


 6.1.5 If an order of a court having jurisdiction over the Company requires you to resign.




 


6.2      Any termination of this letter of appointment shall be without payment of damages or compensation (except that you shall
be entitled to any accrued Fees or Expenses properly incurred under the terms of this letter of appointment prior to the date of
such termination).


 


7.         The
Company will put directors’ and officers’ liability insurance in place within sixty (60) days of this Agreement if
not already in place, and will use commercial reasonable efforts to maintain such insurance coverage for the full term of your
appointment.


 


8.          On termination of this appointment, you shall return all property belonging to the Group, together with all documents, papers,
disks and information, howsoever stored, relating to the Group and used by you in connection with your position with the Company.


 


 


 






    	 	3	 



     


    

 


9.         Subject
to the proper performance of your obligations to the Company under this letter of appointment and any applicable law, the Company
agrees that you will be free to accept other appointments, directorships and chairmanships provided that:


 


 9.1 They do not in any way conflict with the interests of the Company or any member of the Group; and




 


 9.2 They do not restrict you from devoting the necessary time and attention properly to services to be performed under this letter of appointment; and




 


 9.3 In the event that you become aware of any potential conflicts of interest, these must be disclosed to the Chairman and/or the Chief Executive Officer (the "CEO") of the Company as soon as they become apparent.




 


10.       The performance of individual Directors, the Chairman and the Board and its committees is evaluated annually. If, in the
interim, there are any matters which cause you concern about your position, you should discuss them with the Chairman and/or the
CEO as soon as is appropriate.


 


11.       In addition to any right pursuant to applicable law, occasions may arise when you consider that you need professional advice
in the furtherance of your duties as a director. Circumstances may occur when it will be appropriate for you to seek such advice
from independent advisors at the Company’s expense, to the extent provided under applicable law and subject to the prior
written approval of the CEO and/or the Board.


 


12.       This
letter refers to your appointment as a Director of the Company and your membership on the committees of the Board.


 


13.       You shall ensure that you comply at all times with the Company’s inside trading policies as in effect from time to
time.


 


14.       You
shall discharge your general duties as a Director pursuant to the Company's Articles of Incorporation and applicable law.


 


15.        This letter of appointment shall be governed by and construed in accordance with the law of the State of Massachusetts.


 


 


Please sign the attached copy of this letter
and return it to Xenetic to signify your acceptance of the terms set out above.


 


Sincerely yours,


 


XENETIC BIOSCIENCES INC.


 


 


/s/ Jeffrey Eisenberg


Name: Jeffrey Eisenberg Title: Chief Operating Officer


 


AGREED AND ACKNOWLEDGED BY:


 


 


/s/ Adam Logal


Name of Director: Adam Logal


 


 




 


 






    	 	4